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Precision public health has been defined in many ways
[1]. It can be viewed as an emerging multidisciplinary
field that uses genomics, big data, and machine learning/
artificial intelligence to predict health risks and out-
comes and to improve health at the population level.
Just like precision medicine seeks to provide the right
intervention to the right patient at the right time, the
aim of precision public health is to provide the right
intervention to the right population at the right time,
with the goal of improving health for all.
Genomic technologies have been at the leading edge
of applications in clinical medicine and have the poten-
tial to revolutionize public health. We are pleased to
introduce this special issue of Genome Medicine on the
impact of genomics on precision public health, which
highlights the utility of genomic tools in public health
research and practice in the fight against communicable
and noncommunicable diseases. This is particularly
timely, given the battle against the COVID-19 pandemic,
which has necessitated the application of genomic ap-
proaches to track the origin, transmission and evolution
of the SARS-CoV-2 virus globally, as well as to under-
stand differential host susceptibility, response, severity,
and outcomes. Beyond genomics, granular data from
population surveillance approaches are being used to
target public health interventions. In addition, big data,
digital technologies, and mobile health applications have
been instrumental in defining the natural history of
COVID-19 and identifying prognostic factors through
machine learning and artificial intelligence [2].
Human genomics and public health
Genomics plays an emerging role in clinical and public
health research. An increasing number of genomic tests
are available in practice, such as tumor genome analysis
for targeted treatment, non-invasive prenatal screening,
and genomic tests for childhood and rare disorders.
More generally, public health research is needed to as-
sess how genomics fits in an overall ecological model of
health that takes into account the combinations of genes
and environmental, behavioral, and social determinants
[3]. As many common chronic diseases have known en-
vironmental, social, and behavioral risk factors (e.g.,
smoking, physical activity, diet, racial, ethnic and eco-
nomic factors, and access to health care), it is important
to evaluate the benefits, harms and costs of the use of
human genomic information in the prevention and con-
trol of these diseases. Applying genomic tools in practice
will require a multidisciplinary research collaboration
that includes epidemiologists, behavioral, social, and
communication scientists, health services researchers,
and many others [3].
A barrier to using human genomic information for im-
proving population health is poor uptake of evidence-
based interventions and the potential for widening exist-
ing health disparities. Fields such as implementation sci-
ence will be needed to identify the most effective
methods and strategies for integrating the use of gen-
omic applications in population health. Partnerships be-
tween healthcare organizations and public health
programs can help bridge the implementation gap and
reduce health disparities.
To date, newborn screening for treatable inherited
conditions represents the most successful human gen-
omic application in public health, but population screen-
ing across the lifespan for other genetic conditions is
increasingly possible. Abul-Husn et al. report in this
issue that the addition of genomic conditions with high
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prevalence in non-European populations to a genomic
screening program increases the number of non-
European participants choosing to receive results [4]. In
addition, Stranneheim et al. integrate whole genome se-
quencing into the Stockholm-area healthcare system to
aid rare disease diagnosis, making important strides in
clinical-academic partnerships [5].
Other recent studies further highlight the impact of
public health programs in accelerating the identification
of individuals with hereditary cancers in populations
(e.g., Lynch syndrome, hereditary breast and ovarian
cancer) [6]. In order to achieve this, public health activ-
ities must involve the identification of people at risk in
health systems and through testing relatives of affected
individuals, known as cascade screening. Public health
programs can also help monitor implementation of gen-
omic medicine, quantify health disparities in implemen-
tation, and develop approaches to address them.
Other emerging applications include genetic predis-
position to adverse drug effects (pharmacogenomics),
carrier testing of prospective parents, and use of poly-
genic risk scores (PRS) in disease detection and preven-
tion. For example, Isgut et al. show that PRS improve
cardiovascular risk stratification early in life when later-
life risk factors are unknown. By middle age, when many
risk factors are known, improvement attributed to PRS
is marginal for the general population [7]. Even in the
genomics age, a simple family health history assessment
can enhance the delivery of precision medicine in health
care and population settings [8]. Moreover, as millions
of people have sought direct-to-consumer genetic tests,
public health programs can help educate the general
public about the promise and limitations of emerging
tests in improving health, as well as to track the impact
of genomic tests at the population level.
Of note, the special issue presents articles on the eth-
ical implications of the use of genomics in public health
in the COVID-19 era. Lewis and Green [9] discuss how
most of the ethical, legal, and social issues (ELSI) that
apply to single gene diseases—such as the relevance of
results to family members, the approach to secondary
and incidental findings, and the role of expert media-
tors—are also relevant in the applications of PRS in
practice.
Geller et al. [10] review the ethical considerations and
implications of ongoing genomic studies that assess host
factors associated with variability in susceptibility, infect-
ivity, and disease severity in patients with COVID-19, or
those exposed to it. Juengst et al. [11] propose a new
ethical framework to ensure that the benefit of precision
public health interventions based on advances in genom-
ics research is not outweighed by the risks they pose to
individuals, families, and vulnerable segments of the
population.
Infectious disease genomics and public health
Genomics has a similarly important role to play in un-
derstanding and managing infectious disease at both the
individual and population levels, as it can be used to
gain precision with respect to both the pathogen and the
infected host population.
On the pathogen side, whole genome sequencing
(WGS) is fast becoming the standard assay for char-
acterizing infectious diseases and is potentially an in-
credibly rich source of information to guide public
health interventions [12]. For example, pathogen gen-
omics is now widely used for the investigation of
foodborne or hospital outbreaks, and it is increasingly
incorporated into surveillance for clinically important
features such as vaccine antigens (to inform vaccine
composition) and antimicrobial resistance determi-
nants (to inform treatment). Genomics is also increas-
ingly applied for pathogen detection and diagnostics
in the clinic. In this context, DNA sequencing can in-
crease the precision of diagnosis beyond species to
the identification of lineages or variants that may be
associated with different degrees of risk and thus
prompt different responses in terms of clinical man-
agement of the individual patient (e.g. antimicrobial
treatment choice) or public health management (e.g.
triggering infection control or contact tracing).
Infection is a two-way street, and functional genomic
characterization of the host response can also have diag-
nostic and prognostic utility, providing insight into the
nature and extent of immunological responses and help-
ing to identify appropriate treatments for different pa-
tient groups. For example, Aschenbrenner et al. studied
transcriptomes of COVID-19 patients [13], yielding in-
sights into the natural history of disease and highlighting
differences in the immune response of patients with se-
vere vs mild disease. These specific response signatures
were probed to identify potential drugs for therapeutic
repurposing, targeted specifically to those with severe
disease. Being able to more precisely define which host
populations are most at risk of infection through gen-
omic risk prediction is also an attractive proposition that
could have significant impacts on population health by
allowing preventative measures to be targeted to the
most at-risk subgroups, although this comes with the
same ethical concerns as the genomic prediction of non-
communicable disease risk and in fact could intersect
with it. In this special issue, Kachuri et al. [14] identified
genetic variants associated with antibody responses to
antigens for 16 different viruses, many of which were
also associated with non-communicable diseases includ-
ing cancer.
The COVID-19 pandemic has stimulated the re-
finement of methods for rapid high-throughput
pathogen sequencing, such as the CoronaHIT
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method for SARS-CoV-2, published in this special
issue [15], and illustrates some of the ways that real-
time pathogen genome data can be harnessed to in-
form public health strategy in the context of an on-
going epidemic. Genomics is the primary method for
monitoring variation in pathogen populations and
identifying variants that may be of public health con-
cern due to (i) increased transmissibility; (ii) in-
creased severity; (iii) differences in sensitivity/
specificity of current diagnostic tests; and (iv) escape
from interventions, such as host immunity (vaccine-
induced or natural) or sensitivity to drugs. Identifica-
tion of such variants can increase precision of the
public health response, by targeting scarce resources
towards the most concerning variants, for example
community-based testing in areas of England where
importation of potential vaccine-escape variants of
SARS-CoV-2 were detected, or updating diagnostics
and vaccines to ensure coverage of the continually
evolving pathogen population. In addition, phyloge-
nomic analyses can be used to track transmission of
the virus at different spatial scales, such as assessing
the contribution of travel-associated strain introduc-
tions to establishment of the epidemic in a particular
country [16] or investigating within-hospital trans-
mission [17]. The pandemic has also highlighted
challenges associated with generating and sharing se-
quence data in a timely, equitable, and ethical man-
ner, as well as challenges around data visualization,
naming of genetic variants, and communicating re-
sults both within the public health sector and with
the wider public.
It has been suggested that the COVID-19 pandemic
may be amplifying another major global health crisis,
that of antimicrobial resistance [18]. Two articles in this
special issue illustrate the important role of genomics in
understanding and controlling the burden of antimicro-
bial resistant infections in hospitals. Berbel Caban et al
[19] present a method to facilitate the detection of in-
hospital spread of methicillin resistant Staphylococcus
aureus (MRSA or “golden Staph”) by combining gen-
omic and epidemiological data. The genetics of anti-
microbial resistance can be incredibly complex, and for
most pathogens, the overall burden of resistant infec-
tions is the combined result of the spread of resistance
genes and plasmids between bacterial strains and the
transmission of bacterial strains between patients.
Arredondo-Alonso et al [20] use genomics to disentan-
gle and quantify these contributing factors, which could
help to focus infection control efforts in future.
Looking ahead
The field of precision public health is still in its infancy
and genomics will be a major contributor to its growth
in the next decade. The COVID-19 pandemic provides
both a challenge and an opportunity for further evolu-
tion of precision public health, as new tools and tech-
nologies are beginning to complement traditional public
health approaches. In the next decade, additional devel-
opments in the field will require leadership and commit-
ment to enhance data collection and coordination across
geographic boundaries, harmonization and integration of
different types of data beyond genomics, and robust as-
sessment of ethical, legal, and social implications of new
technologies for the benefits of humanity worldwide.
Many of these issues are currently being tackled by the
recently formed Public Health Alliance for Genomic Epi-
demiology [21], which aims to improve openness, inter-
operability, accessibility, and reproducibility in public
health microbial informatics globally. As the COVID-19
pandemic clearly shows, we need the tools of genomics
more than ever before in the fight against infectious dis-
eases. Beyond fighting outbreaks, genomics will become
an essential component of public health in the twenty-
first century for communicable and noncommunicable
diseases.
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